Effect of Antihypertensive and Statin Medication Use on Muscle Performance in Community-Dwelling Older Adults Performing Strength Training
暂无分享,去创建一个
B. Bravenboer | I. Bautmans | I. Beyer | T. Mets | A. Delaere | Mohammad Alturki | S. Lieten | Keliane Liberman | L. De Dobbeleer | V. Knoop
[1] I. Bautmans,et al. Six weeks of strength endurance training decreases circulating senescence-prone T-lymphocytes in cytomegalovirus seropositive but not seronegative older women , 2019, Immunity & Ageing.
[2] I. Bautmans,et al. Impact of drugs with anti-inflammatory effects on skeletal muscle and inflammation: A systematic literature review , 2018, Experimental Gerontology.
[3] L. Ferrucci,et al. International Clinical Practice Guidelines for Sarcopenia (ICFSR): Screening, Diagnosis and Management , 2018, The journal of nutrition, health & aging.
[4] I. Bautmans,et al. Strength endurance training but not intensive strength training reduces senescence-prone T-cells in peripheral blood in community-dwelling elderly women. , 2018, The journals of gerontology. Series A, Biological sciences and medical sciences.
[5] René Rizzoli,et al. Sarcopenia: revised European consensus on definition and diagnosis , 2018, Age and ageing.
[6] S. Vermeiren,et al. Association Between Immunosenescence Phenotypes and Pre-frailty in Older Subjects: Does Cytomegalovirus Play a Role? , 2018, The journals of gerontology. Series A, Biological sciences and medical sciences.
[7] Y. Fujiwara,et al. Association between statin use and physical function among community‐dwelling older Japanese adults , 2018, Geriatrics & gerontology international.
[8] M. Tinetti,et al. Guideline‐Recommended Medications and Physical Function in Older Adults with Multiple Chronic Conditions , 2017, Journal of the American Geriatrics Society.
[9] P. Thompson,et al. The effects of statins on exercise and physical activity. , 2017, Journal of clinical lipidology.
[10] M. Veríssimo,et al. Exercise training improves functional status in hypertensive older adults under angiotensin converting enzymes inhibitors medication , 2017, Experimental Gerontology.
[11] H. Völzke,et al. Statins are related to impaired exercise capacity in males but not females , 2017, PloS one.
[12] E. Steinhagen-Thiessen,et al. Angiotensin-Converting Enzyme Inhibitors and Parameters of Sarcopenia: Relation to Muscle Mass, Strength and Function: Data from the Berlin Aging Study-II (BASE-II) , 2016, Drugs & Aging.
[13] M. Serra-Prat,et al. Oral Drugs Related with Muscle Wasting and Sarcopenia. A Review , 2016, Pharmacology.
[14] J. Verghese,et al. Gait Performance in Hypertensive Patients on Angiotensin-Converting Enzyme Inhibitors. , 2016, Journal of the American Medical Directors Association.
[15] R. Halfens,et al. Burden-of-illness of Dutch community-dwelling older adults with sarcopenia: health related outcomes and costs , 2016 .
[16] G. Peeters,et al. Associations Between Statin Use and Physical Function in Older Adults from The Netherlands and Australia: Longitudinal Aging Study Amsterdam and Australian Longitudinal Study on Women’s Health , 2016, Drugs & Aging.
[17] V. Probst,et al. Angiotensin-II blockage, muscle strength, and exercise capacity in physically independent older adults , 2016, Journal of physical therapy science.
[18] B. Tomlinson,et al. Achievement of specified lipid and high-sensitivity C-reactive protein levels with two statins in Chinese patients with hypercholesterolaemia , 2015, Lipids in Health and Disease.
[19] Y. Chang,et al. Angiotensin II in inflammation, immunity and rheumatoid arthritis , 2015, Clinical and experimental immunology.
[20] Jeffrey R Stout,et al. Prevalence of and interventions for sarcopenia in ageing adults: a systematic review. Report of the International Sarcopenia Initiative (EWGSOP and IWGS) , 2014, Age and ageing.
[21] P. Cawthon,et al. Statins and physical activity in older men: the osteoporotic fractures in men study. , 2014, JAMA internal medicine.
[22] L. Vilá,et al. Association of the use of statins with disease activity and functional status in Puerto Ricans with rheumatoid arthritis. , 2014, Puerto Rico health sciences journal.
[23] C. Tzourio,et al. Lipid-lowering drugs associated with slower motor decline in the elderly adults. , 2014, The journals of gerontology. Series A, Biological sciences and medical sciences.
[24] M. Mcmurdo,et al. Do ACE Inhibitors Improve the Response to Exercise Training in Functionally Impaired Older Adults? A Randomized Controlled Trial , 2013, The journals of gerontology. Series A, Biological sciences and medical sciences.
[25] M. Levy,et al. Effect of ramipril on walking times and quality of life among patients with peripheral artery disease and intermittent claudication: A randomized controlled trial. Journal of the American Medical Association 2013; 309: 453–460 , 2013, Vascular medicine.
[26] Rose Anne Kenny,et al. Using timed up-and-go to identify frail members of the older population. , 2013, The journals of gerontology. Series A, Biological sciences and medical sciences.
[27] C. Reid,et al. Effect of ramipril on walking times and quality of life among patients with peripheral artery disease and intermittent claudication: a randomized controlled trial. , 2013, JAMA.
[28] M. Brotto,et al. Sarcopenia: Pharmacology of Today and Tomorrow , 2012, Journal of Pharmacology and Experimental Therapeutics.
[29] Jennifer G. Robinson,et al. Statins, Angiotensin‐Converting Enzyme Inhibitors, and Physical Performance in Older Women , 2012, Journal of the American Geriatrics Society.
[30] P. Thompson,et al. Effect of Statins on Skeletal Muscle Function , 2012, Circulation.
[31] S. Anton,et al. Angiotensin‐Converting Enzyme Inhibitor Use by Older Adults Is Associated with Greater Functional Responses to Exercise , 2012, Journal of the American Geriatrics Society.
[32] K. Channon,et al. Statins as Anti-Inflammatory Agents in Atherogenesis: Molecular Mechanisms and Lessons from the Recent Clinical Trials , 2012, Current pharmaceutical design.
[33] M. Bernabeu-Wittel,et al. Effects of renin-angiotensin blockers/inhibitors and statins on mortality and functional impairment in polypathological patients. , 2012, European journal of internal medicine.
[34] Martin R. Lindley,et al. The anti-inflammatory effects of exercise: mechanisms and implications for the prevention and treatment of disease , 2011, Nature Reviews Immunology.
[35] G. Onder,et al. Current and future pharmacologic treatment of sarcopenia. , 2011, Clinics in geriatric medicine.
[36] F. Lattanzio,et al. Targeting inflammation to slow or delay functional decline: where are we? , 2010, Biogerontology.
[37] P. Joshi,et al. Therapeutic Options to Further Lower C-Reactive Protein for Patients on Statin Treatment , 2010, Current atherosclerosis reports.
[38] J. Woo,et al. Defining Sarcopenia in Terms of Risk of Physical Limitations: A 5‐Year Follow‐Up Study of 3,153 Chinese Men and Women , 2009, Journal of the American Geriatrics Society.
[39] G. Onder,et al. Validated treatments and therapeutics prospectives regarding pharmacological products for sarcopenia , 2009, The journal of nutrition, health & aging.
[40] L. Blizzard,et al. Statin therapy, muscle function and falls risk in community-dwelling older adults. , 2009, QJM : monthly journal of the Association of Physicians.
[41] B. Miller,et al. The interactions of some commonly consumed drugs with mitochondrial adaptations to exercise. , 2009, Journal of applied physiology.
[42] S. Kritchevsky,et al. Angiotensin-converting enzyme inhibition and novel cardiovascular risk biomarkers: results from the Trial of Angiotensin Converting Enzyme Inhibition and Novel Cardiovascular Risk Factors (TRAIN) study. , 2009, American heart journal.
[43] M. Mcmurdo,et al. ACE inhibitors as a therapy for sarcopenia — Evidence and possible mechanisms , 2008, The journal of nutrition, health & aging.
[44] M. Mcmurdo,et al. ACE inhibitors for sarcopenia--as good as exercise training? , 2008, Age and ageing.
[45] B. Horne,et al. Comparison of effects of high (80 mg) versus low (20 mg) dose of simvastatin on C-reactive protein and lipoproteins in patients with angiographic evidence of coronary arterial narrowing. , 2007, The American journal of cardiology.
[46] M. Mcmurdo,et al. Sarcopenia – A Potential Target for Angiotensin-Converting Enzyme Inhibition? , 2006, Gerontology.
[47] M. Pahor,et al. Effects of ACE inhibitors on skeletal muscle. , 2006, Current pharmaceutical design.
[48] R. Devereux,et al. Exercise performance during losartan‐ or atenolol‐based treatment in hypertensive patients with electrocardiographic left ventricular hypertrophy (a LIFE substudy) , 2006, Blood pressure.
[49] A. Ducharme,et al. Angiotensin Receptor Blockade and Exercise Capacity in Adults With Systemic Right Ventricles: A Multicenter, Randomized, Placebo-Controlled Clinical Trial , 2005, Circulation.
[50] Tony Mets,et al. A fatigue resistance test for elderly persons based on grip strength: reliability and comparison with healthy young subjects , 2005, Aging clinical and experimental research.
[51] Tony Mets,et al. The six-minute walk test in community dwelling elderly: influence of health status. , 2004, BMC geriatrics.
[52] M. Lye,et al. The Effect of Quinapril on Functional Status of Elderly Patients with Diastolic Heart Failure , 2003, Cardiovascular Drugs and Therapy.
[53] T. Mets,et al. The 6-minute walk as an appropriate exercise test in elderly patients with chronic heart failure. , 1996, The journals of gerontology. Series A, Biological sciences and medical sciences.
[54] H. Müller-Hermelink,et al. Admission criteria for immunogerontological studies in man: The senieur protocol , 1984, Mechanisms of Ageing and Development.
[55] J. Reid,et al. Lecture Notes on Clinical Pharmacology , 1982 .
[56] M. Cesari,et al. ACE-inhibition and physical function: results from the Trial of Angiotensin-Converting Enzyme Inhibition and Novel Cardiovascular Risk Factors (TRAIN) study. , 2010, Journal of the American Medical Directors Association.